Clinical trials: Breakthrough Cancer Pain
Pain
Fentanyl for Breakthrough Pain in the Emergency Department
The goal of this clinical research study is to learn if fentanyl nasal spray can help decrease pain related to cancer when used with other drugs for pain.
- Trial name
- NCT01812759
- Testing
- Fentanyl Nasal Spray, Hydromorphone PCA
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- M.D. Anderson Cancer Center
Cancer, Pain
A Study for the Evaluation of the Safety, Tolerability, and Efficacy of ARX-F02 (Sufentanil NanoTab) Compared to Placebo in the Treatment of Cancer Breakthrough Pain
The purpose of this research study was to evaluate ARX-F02 (Sufentanil NanoTab) versus placebo ("sugar" pill or inactive substance) in the management of breakthrough pain in cancer patients.
- Trial name
- NCT00833040
- Where
- 13 sites in United States
- Volunteers
- 34 people
- Sponsor
- Talphera, Inc
Advanced Cancers
Sublingual Fentanyl for the Management of Breakthrough Pain
The goal of this clinical research study is to learn if an investigational dose of fentanyl sublingual spray (FSS) can help to control pain in patients with advanced cancer when given in an outpatient and inpatient setting.
- Trial name
- NCT02514252
- Testing
- Fentanyl Sublingual Spray (FSS), Questionnaires, Mental Ability Tests
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- M.D. Anderson Cancer Center
Pain, Cancer
Long-term Safety Study of Sublingual Fentanyl Tablets in Cancer Patients
The purpose of this study is to evaluate the long-term safety and effectiveness of EN3267 in treating breakthrough pain episodes in opioid cancer patients who are using stable doses of opioid medication.
- Trial name
- NCT00263575
- Testing
- EN3267
- Where
- United States
- Volunteers
- 139 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Cancer Pain, Breakthrough Pain
Study of Breakthrough Cancer Pain: Assessment of Fentanyl Buccal Tablets Titration and Treatment in Opioid-Tolerant Patients
Breakthrough cancer pain (BTcP) is a common problem in patients with cancer. Fentanyl Buccal Tablet (FBT) is used for the treatment of BTP in adults with cancer who are already receiving maintenance opioid therapy for chronic…
- Trial name
- NCT00842829
- Testing
- Fentanyl Buccal Tablet (FBT)
- Where
- 123 sites in France, Germany and 5 more
- Volunteers
- 330 people
- Sponsor
- Cephalon
Break Through Pain, Cancer
A Clinical Trial With Intranasal Fentanyl in Cancer Patients With Breakthrough Pain
The aim of this clinical trial was to demonstrate the efficacy of a 400 μg dose strength of intranasal fentanyl spray (INFS, Instanyl®) and to evaluate the safety and to establish long term tolerability of treatment with INFS…
- Trial name
- NOSE-400 (NCT01429051)
- Testing
- Intranasal Fentanyl Spray (INFS)
- Where
- 11 sites in Hungary, Norway and 1 more
- Volunteers
- 46 people
- Sponsor
- Takeda
Breakthrough Cancer Pain
Characterisation and Epidemiology of Breakthrough Cancer Pain in Spain
The purpose of this study is to determine the prevalence of breakthrough cancer pain and characterize breakthrough cancer pain in an unselected, representative cohort of cancer outpatients with or without pain who attend…
- Trial name
- NCT02899884
- Testing
- No Intervention
- Where
- 36 sites in Spain
- Volunteers
- 3,765 people
- Sponsor
- Takeda
Cancer, Pain
Long-term Safety and Efficacy Study of Fentanyl Sublingual Spray for the Treatment of Breakthrough Cancer Pain
The purpose of this study was to assess the 90-day safety of fentanyl sublingual spray for the treatment of breakthrough cancer pain in subjects on around-the-clock opioids for their persistent cancer pain.
- Trial name
- NCT00538863
- Testing
- Fentanyl sublingual spray
- Where
- 52 sites in United States, Canada and 1 more
- Volunteers
- 319 people
- Sponsor
- INSYS Therapeutics Inc
Respiratory Depression
Long-term Extension Study of BEMA™ Fentanyl
This study is designed to provide continued access to BEMA Fentanyl for those subjects who previously participated in FEN-202 and who wish to continue using BEMA Fentanyl for the treatment of their breakthrough cancer pain.
- Trial name
- NCT00696137
- Testing
- BEMA Fentanyl
- Volunteers
- 5 people
- Sponsor
- BioDelivery Sciences International
Pain, Cancer
Study of BEMA™ Fentanyl in the Treatment of Breakthrough Pain in Cancer Subjects
The purpose of this study is to evaluate the efficacy of BEMA Fentanyl (Onsolis) at any dose in the management of breakthrough pain in cancer subjects on background opioid therapy.
- Trial name
- NCT00293033
- Testing
- BEMA™
- Where
- United States
- Volunteers
- 152 people
- Sponsor
- BioDelivery Sciences International
Breakthrough Pain, Cancer
Efficacy and Tolerability of Intranasal Fentanyl Spray for the Treatment of Breakthrough Pain in Cancer Patients Older Than 18 Years
The aim of the study was to evaluate the safety and efficacy of intranasal fentanyl spray in cancer patients over four weeks, especially during cancer-related breakthrough pain (BTP) attacks.
- Trial name
- GENISIS (NCT00994760)
- Testing
- Instanyl (Intranasal Fentanyl)
- Where
- 168 sites in Germany
- Volunteers
- 131 people
- Sponsor
- Takeda
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Cancer, Pain
An Efficacy and Safety Study of Hydromorphone Hydrochloride (HCl) Oral Osmotic System (OROS) in the Reduction of Breakthrough Pain Medication Frequency in Participants With Cancer
The purpose of this study is to evaluate the clinical efficacy of hydromorphone hydrochloride (HCl) Oral Osmotic System (OROS) by assessing the extent of reduction of medication frequency for the management of breakthrough pain…
- Trial name
- NCT01006356
- Testing
- Hydromorphone HCl OROS
- Volunteers
- 141 people
- Sponsor
- Janssen Korea, Ltd., Korea
Pain, Cancer
Study of the Safety of BEMA™ Fentanyl Use for Breakthrough Pain in Cancer Subjects on Chronic Opioid Therapy
The purpose of this study is to evaluate the safety of BEMA fentanyl at any dose in the management of breakthrough pain in cancer subjects on background opioid therapy.
- Trial name
- NCT00293020
- Testing
- BEMA Fentanyl
- Where
- United States
- Volunteers
- 244 people
- Sponsor
- BioDelivery Sciences International